GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Goodwill

XLO (Xilio Therapeutics) Goodwill : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Xilio Therapeutics's goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil.


Xilio Therapeutics Goodwill Historical Data

The historical data trend for Xilio Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics Goodwill Chart

Xilio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial - - - - -

Xilio Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xilio Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Xilio Therapeutics  (NAS:XLO) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Xilio Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/71.075
=0.00

Xilio Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/71.075
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Xilio Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Xilio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
828 Winter Street, Suite 300, Waltham, MA, USA, 02451
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Executives
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova officer: Chief Medical Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield officer: Chief Operating Officer C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan officer: SVP, FINANCE AND ACCOUNTING C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English officer: Principal Accounting Officer 828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp 10 percent owner 71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p. 10 percent owner 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105